anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A strain-hardened interpenetrating polymer network (IPN) hydrogel is provided. The interpenetrating polymer network hydrogel is based on two different networks. The first network is a non-silicone network of preformed hydrophilic non-ionic telechelic macromonomers chemically cross-linked by polymerization of its end-groups. The second network is a non-silicone network of ionizable monomers. The second network has been polymerized and chemically cross-linked in the presence of the first network and has formed physical cross-links with the first network. An aqueous salt solution having a neutral pH is used to ionize and swell the second network in the interpenetrating polymer network. The swelling of the second network is constrained by the first network, and this constraining effect results in an increase in effective physical cross-links within the interpenetrating polymer network, and, in turn, an increase its elastic modulus. The strain-hardened interpenetrating polymer network hydrogel is attractive and useful for medical, industrial, and personal hygiene purposes.
Do not administer unless solution is clear and container is intact. Discard unused portion.

It is sometimes advisable to make a trial injection of procaine or other local anesthetic prior to alcohol injection as a means of confirming accurate placement of the needle, and to decrease pain experienced during the procedure. X-ray visualization for precise placement also may be advisable.

When used for selective sensory block within the subarachnoid space, it is essential to avoid contact of the alcohol with the anterior (motor) roots of the spinal nerve to be treated if motor paralysis is not desired. When peripheral nerves are injected, care should be taken that residual alcohol is not deposited along the needle track or in any other locations where tissue destruction is not wanted. Instances have been reported in which the pain resulting from post-injection neuritis was more severe than that existing before the injection.

Pregnancy

Pregnancy Category C: Animal reproduction studies have not been conducted with dehydrated alcohol. It is also not known whether dehydrated alcohol can cause fetal harm when given to a pregnant woman or can affect reproduction capacity. Dehydrated alcohol should be given to a pregnant woman only if clearly needed.
In patients with depression, a possibility for suicide should be borne in mind; benzodiazepines should not be used in such patients without adequate antidepressant therapy.

Lorazepam should be used with caution in patients with compromised respiratory function (e.g., COPD, sleep apnea syndrome).

Elderly or debilitated patients may be more susceptible to the sedative effects of lorazepam. Therefore, these patients should be monitored frequently and have their dosage adjusted carefully according to patient response; the initial dosage should not exceed 2 mg.

Paradoxical reactions have been occasionally reported during benzodiazepine use. Such reactions may be more likely to occur in children and the elderly. Should these occur, use of the drug should be discontinued.

The usual precautions for treating patients with impaired renal or hepatic function should be observed. As with all benzodiazepines, the use of lorazepam may worsen hepatic encephalopathy; therefore, lorazepam should be used with caution in patients with severe hepatic insufficiency and/or encephalopathy. Dosage for patients with severe hepatic insufficiency should be adjusted carefully according to patient response; lower doses may be sufficient in such patients.

In patients where gastrointestinal or cardiovascular disorders coexist with anxiety, it should be noted that lorazepam has not been shown to be of significant benefit in treating the gastrointestinal or cardiovascular component.

Esophageal dilation occurred in rats treated with lorazepam for more than one year at 6 mg/kg/day. The no-effect dose was 1.25 mg/kg/day (approximately 6 times the maximum human therapeutic dose of 10 mg per day). The effect was reversible only when the treatment was withdrawn within two months of first observation of the phenomenon. The clinical significance of this is unknown. However, use of lorazepam for prolonged periods and in geriatric patients requires caution, and there should be frequent monitoring for symptoms of upper GI disease.

Safety and effectiveness of lorazepam in children of less than 12 years have not been established.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is an increasingly common complication of obesity, affecting over a quarter of the global adult population. A key event in the pathophysiology of MASLD is the development of metabolic-associated steatohepatitis (MASH), which greatly increases the chances of developing cirrhosis and hepatocellular carcinoma. The underlying cause of MASH is multifactorial, but accumulating evidence indicates that the inflammatory process in the hepatic microenvironment typically follows a pattern that can be roughly divided into three stages: (1) Detection of hepatocyte stress by tissue-resident immune cells including γδ T cells and CD4-CD8- double-negative T cells, followed by their secretion of pro-inflammatory mediators, most notably IL-17A. (2) Recruitment of pro-inflammatory cells, mostly of the myeloid lineage, and initiation of inflammation through secretion of effector-type cytokines such as TNF, TGF-β, and IL-1β. (3) Escalation of the inflammatory response by recruitment of lymphocytes including Th17, CD8 T, and B cells leading to chronic inflammation, hepatic stellate cell activation, and fibrosis. Here we will discuss these three stages and how they are consecutively linked like falling domino tiles to the pathophysiology of MASH. Moreover, we will highlight the clinical potential of inflammation as a biomarker and therapeutic target for the treatment of MASLD.
The present invention relates to methods and compositions for treating tumors. In one aspect, the present invention relates to an injection comprising 0.001% to 0.2% aluminum sulfate on an anhydrous basis, and water for injection. The injection can also contain local anesthetic; such as a local anesthetic selected from: lidocaine, procaine, chloroprocaine, tetracaine, cocaine, dibucaine, prilocaine, mepivacaine, bupivacaine, etidocaine, methocaine, ropivacaine, pirocaine or dyclonine, preferably lidocaine such as lidocaine hydrochloride. The injection can also contain a coloring agent selected from the following group: methylene blue, indigo, brilliant blue, patent blue V, gentian violet, copper sulfate, chlorophyll, sodium iron chlorophyllin, copper chlorophyllin, complex salt of copper chlorophyllin, sodium copper chlorophyllin, fast green, preferably methylene blue. The invention also relates to application of the injection in preparing a medicament for treating tumors. The injection of the invention has excellent effect of inhibiting the growth of tumor.
NEW MATERIAL:cis-3-Hexenyl p-methoxybenzoate expressed by the formula. USE:A perfume raw material. Green which is slightly metallic and characteristic has leaf-like perfume and is blended with various kind of perfume compositions to be able to provide a product having excellent functional characteristics. PREPARATION:p-Methoxybenzoic acid is subjected to esterification reaction to provide the compound expressed by the formula. The compound is a anisic acid ester-based compound and slightly exists in an essential oil extracted from Lilium longiflorum Thunb. the compound can be blended with a perfume composition such as perfume, cologne, champ, rinse, lotion, soap, cleanser, aromatic, etc., and is blended in an amount of 0.1-30wt.% based on the perfume composition.
Risk of vascular disease including stroke, myocardial infarction, and vascular death is high after stroke but there are only few prognostic models for long term risk up to 3 years. About 850 patients with an incident stroke will be followed for 3 years with assessments at baseline and at 3, 12, 24, and 36 months. Factors that have already been reported to be significant predictors of vascular diseases in previous studies as well as new biomarkers (e.g. neuroimaging, blood based biomarkers) identified in this cohort will be considered. The improvement of discrimination including these new variables in the models will be investigated. Several measures of improving predictive properties (e.g. calibration, discrimination, net reclassification) will be used to compare predictive models with different complexity. The model will be validated using the bootstrap method (internal validation) and an independent external sample in cooperation with the Institute for Stroke and Dementia Research, Munich.
To provide a method for treating a disease.SOLUTION: The present disclosure relates generally to modulators of Cot (cancer Osaka thyroid) of general formula (I) and methods of use and manufacture thereof. The present disclosure provides compounds that modulate the expression or activity of Cot. The disclosure also provides compositions, including pharmaceutical compositions, kits that include the compounds, and methods of using (or administering) and making the compounds. The compounds provided herein can be useful in treating diseases, disorders, or conditions that are mediated by Cot. The disclosure also provides compounds for use in therapy. The disclosure further provides compounds for use in a method of treating a disease, disorder, or condition that is mediated by Cot. Moreover, the disclosure provides uses of compounds in the manufacture of a medicament for the treatment of a disease, disorder or condition that is mediated by (or mediated, at least in part, by) Cot.SELECTED DRAWING: Figure 1
The invention relates to the fields of biotechnology, virology, epidemiology and public health, and is method for obtaining of new inactivated vaccine against coronavirus COVID-19. The essence matter of invention is COVID-19 virus "SARS-CoV-2/KZ_Almaty/04.2020" strain isolated on the territory of the Republic of Kazakhstan. The strain of COVID-19 virus according to the optimal cultivation conditions is produced in the Vero cell culture system, inactivated by formaldehyde, clarified by low-speed centrifugation, purified and concentrated by diafiltration on diafiltration unit of Millipore Pellicon Cassette system. Sterilizing filtration is carried out through cascades of filters with a pore diameter of 0.45/0.22 μm. 2 % aluminum hydroxide gel "Algidrogel, 85" is added in the obtained virus pool (viral concentrate) to final concentration of 0.5 mg/0.5 ml and bottled in glass vials. The vaccine obtained in this way is safe at intraperitoneal introduction to white mice and intravenously - to rabbits. The vaccine provides 80 % protection against COVID-19 infection for at least 6 months after two vaccinations. The vaccine keeps its properties for 12 months at 4-6°C.
The invention relates to an anti-tumor racemization or optical pure trans-2, 3-diacyl indoline compound and a synthesis method thereof, belonging to the technical field of chemical pharmacy. In particular to a trans-2, 3-diacyl indoline compound shown in a formula I and application thereof in preparing antitumor drugs. The structural general formula of the trans-2, 3-diacyl indoline compound is shown as the following formula I. The compounds can be racemic compounds or haveHas optical activity. The trans-2, 3-diacyl indoline compound is produced by reacting 3, N-diacyl indole with formyl compound under the condition that tetrabutylammonium decatungstate (TBADT) is taken as a photocatalyst. The trans-2, 3-diacyl substituted indoline compound shown in the formula I has biological activity of inhibiting proliferation of tumor cells, and can be used for preparing antitumor drugs.
A composition for administration to a subject is disclosed. The composition comprises at least one plant active ingredient. The plant active ingredient is present in the composition in an amount effective to inhibit collagenase activity in the skin of a subject. The plant active component comprises at least one extract selected from the group consisting of: i) An extract of lonicera leaf; ii) an extract of kapok; iii) Extracts of the fruit of Alpinia galanga; iv) extract of dogwood fruit; and v) combinations of i) to iv). The composition may be in the form of a topical composition, e.g. for topical administration. The composition may also be in the form of an oral composition, for example for ingestion. Also provided is a method of inhibiting collagenase activity in the skin of a subject. The method comprises administering to a subject an effective amount of the composition.
Patients undergo collection of blood samples at the time of the initial diagnostic work-up, and possibly prior to the initiation of surgery, chemotherapy, immunotherapy, or radiation therapy, at tumor progression or recurrence, and annually during routine follow-up (no more than 4 blood draws per year). Patients may also undergo collection of tissue sample during standard of care surgical or radiologic procedures. Healthy individuals undergo collection of blood samples up to 4 times over 1 year.
Methods for treating photoablated corneal tissue are described. The methods include contacting photoablated corneal tissue with a contact lens which includes an amniotic composition such that scarring of the photoablated corneal tissue is reduced. Methods for conditioning a contact lens for treatment of photoablated corneal tissue are also described. The methods include contacting the contact lens with an amniotic composition whereby the amniotic composition is deposited in or on the surface of said contact lens. Additionally, contact lens packages for treatment of photoablated corneal tissue are described. The contact lens package includes a container holding a contact lens which includes an amniotic composition and instructions for using the contact lens for treatment of photoablated corneal tissue.
A 6 month intervention consisting of two phases: Phase I Intensive intervention is 12 weekly sessions that alternate between a group-based clinic session (concurrent parent and child groups) and individual home visits. Phase II Maintenance is 12 weeks of every other week visits alternating between clinic and home. Treatment targets 3 components: Dietary education, physical activity and parenting training.
The invention relates to a method for people to inhale hydrogen-contained air or/ and oxygen and a business model. The method for the people to inhale the hydrogen-contained air or/ and oxygen and the business model are characterized in that oxygen-hydrogen mixture prepared from electrolyzed water is mixed with air or/ and oxygen, and the obtained mixture is inhaled by people in place or/ and is conveyed out of sites for business operation for people to inhale via a container or a pipeline. The sites for business operation are entity sites, can be installed on a place for selling and providing service and also can be installed on other places for people to spread information. A plurality of sites for business operation can be arranged and form a chain and/ or franchised business operation system. The method for the people to inhale the hydrogen-contained air or/ and oxygen and the business model are combined with the Internet, and the terminals of the off-line sites for business operation and an on-line e-commerce platform carry out data sharing and collection to realize seamless connection and optimal integration. The method for the people to inhale the hydrogen-contained air or/ and oxygen and the business model can meet the requirement that people conveniently and safely inhale the hydrogen-contained air or/ and oxygen.
The purpose of this study is to determine if the pain and anxiety that children experience when they have venipuncture procedures performed can be reduced by a video-based distraction and coping strategy intervention. An instructional video has been designed to educate parents and children about what is going to happen during the venipuncture procedure; to teach coping skills that can be used before and during the painful procedure; and to provide distraction during the procedure by using an entertaining video segment.

Approximately 168 children (6-12 years of age)who are seen in the IWK ED requiring venipunctures for blood collection or IV starts will be randomized. PArent and child training in distraction and coping strategies will be provided by means of a self-administered video-delivery via a portable DVD player. Fifty percent of the eligible participants will receive the distraction and coping strategies intervention and 50% will receive the standard medical care provided by the IWK ED. Those receiving standard care will be evaluated for outcome results and then be compared to the intervention group. It is expected that children who receive the intervention will report less pain and anxiety associated with venipunctures than those who receive standard care.
Beta-carotene, retinol, and retinal have effective and reliable vitamin A activity. Retinal and retinol are in chemical equilibrium in the body and have equivalent antixerophthalmic activity. Retinal combines with the rod pigment, opsin, in the retina to form rhodopsin, necessary for visual dark adaptation. Vitamin A prevents retardation of growth and preserves the epithelial cells' integrity. Normal adult liver storage is sufficient to satisfy two years' requirements of vitamin A.

Vitamin A is readily absorbed from the gastrointestinal tract, where the biosynthesis of vitamin A from beta-carotene takes place. Vitamin A absorption requires bile salts, pancreatic lipase, and dietary fat. It is transported in the blood to the liver by the chylomicron fraction of the lymph. Vitamin A is stored in Kupffer cells of the liver mainly as the palmitate. Normal serum vitamin A is 80–300 Units per 100 mL (plasma range is 30–70 mcg per dl) and for carotenoids 270–753 Units per 100 mL. The normal adult liver contains approximately 100 to 300 micrograms per gram, mostly as retinol palmitate.

*Oil-soluble vitamin A water solubilized with polysorbate 80.
The invention provides health-care tea with effects of relieving sore throat and eliminating phlegm, as well as a preparation method and application thereof, and relates to the technical field of medical care. The health-care tea is mainly prepared from the following materials in parts by weight: 1-80 parts of gynostemma pentaphyllum, 2-50 parts of ginseng leaves, 1-50 parts of poria cocos, 1-50 parts of platycodon grandiflorum and 1-40 parts of liquorice. The health-care tea conforms to the assistant and guide composition rules of the traditional Chinese medicine and mainly has the effects of benefiting qi for promoting production of fluid as well as relieving sore throat and eliminating phlegm. The gynostemma pentaphyllum has the effects of benefiting qi for promoting production of fluid as well as relieving sore throat and eliminating phlegm; the ginseng leaves have the effects of promoting production of body fluid and moistening dryness as well as replenishing lung qi; the poria cocos and the platycodon grandiflorum have the effects of invigorating the spleen and eliminating dampness as well as ventilating the lung and eliminating phlegm; the liquorice has the effects of clearing heat and removing toxins as well as moistening the lung and arresting cough; and all the medicines are mixed. The preparation method comprises the step of grinding the materials. The preparation method is simple and strong in operability and is beneficial to industrial production. The invention also provides the application of the health-care tea in preparing medicines, foods and health-care products for treating cough and asthma.
This invention generally relates to a design and method for developing novel antitumor/cancer drugs, vaccines and therapies, using microRNA (miRNA) and its shRNA homologues/derivatives. More particularly, the present invention relates to the use of a nucleic acid composition capable of expressing mir-302-like gene silencing effectors upon delivery into human cells and then silencing mir-302-targeted cell cycle regulators and oncogenes, resulting in an inhibitory effect on tumor/cancer cell growth and metastasis. Mir-302 is the most predominant miRNA found in human embryonic stem (hES) and induced pluripotent stem (iPS) cells, yet its function is unclear. The present invention establishes that in humans mir-302 concurrently suppressed both cyclin-E-CDK2 and cyclin-D-CDK4/6 pathways and eventually blocked over 70% of the G1-S transition. Simultaneously, mir-302 also silences BMI-1, a cancer stem cell marker, and subsequently promotes the tumor suppressor functions of p16Ink4a and p14/p19Arf in inhibiting CDK4/6-mediated cell proliferation. Therefore, the present invention for the first time reveals the tumor suppressor function of mir-302 in humans. This novel finding advances the design and method for developing new cancer drugs, vaccines and therapies directed against multiple kinds of human tumors and cancers, in particular including, but not limited, malignant skin, prostate, breast and liver cancers as well as various tumors.
The invention discloses a juqianxiangku powder used for treating chronic nephritis. The powder comprises 30 g of Japanese thistle root, 10 g of prunella spike, 10 g of wild chrysanthemum flower, 15 g of plantain seed and 4 g of birthwort root, and is prepared by smashing the raw materials by a smashing machine and mixing. The dosage is 74 g. The materials of a dosage are smashed, sieved and evenly divided into 70-72 parts. Each 3-4 g of the powder is taken for a course of treatment which is six days. Taking the powder continuously for 1-2 months can achieve an improvement of disease. For a patient with serious disease, the dosage is increased by 1-2 parts. Beneficial effects of the powder are good effects and low cost.
Stroke patients admitted to the stroke unit, St Olav´s hospital, Trondheim, Norway, without previous stroke, neurological disease or central nervous system (CNS) trauma, will be eligible for inclusion into the study. The planned cohort size is 135 patients.
BACKGROUND: We calculated psoas muscle area (PMA) z-scores in high-risk neuroblastoma patients undergoing treatment to examine the clinical significance of sarcopenia in this cohort.
METHODS: We analyzed retrospective data from patients aged 0-18 who were diagnosed with abdominal neuroblastoma between 2005 and 2019 at Samsung Medical Center. Patients categorized as high-risk undergone induction chemotherapy, neuroblastoma excision, and tandem high-dose chemotherapy with autologous stem cell transplantation (HDCT/auto-SCT) were selected. L3-4 lumbar levels on axial CT images were identified and we measured the areas of the left and right psoas muscles to determine tPMA. Total PMA z-scores were calculated using an open online tool.
RESULTS: There were 45 boys and 25 girls with a mean age of 3.86 years. CT images taken at initial diagnosis and after tandem HDCT/auto-SCT were selected to calculate tPMA z-scores. Mean elapsed time between the two measurements was 12.91 ± 1.73 months. Mean tPMA z-score significantly decreased from -0.21 ± 1.29 to -0.66 ± 0.97 (p = 0.022). Length of hospital stay was significantly longer in the group of patients whose tPMA z-scores decreased by more than .45 (177.62 ± 28.82 days vs. 165.75 ± 21.34 days, p = 0.049). Presence of sarcopenia at initial diagnosis was a significant risk factor for bacterial infection during neuroblastoma treatment.
CONCLUSION: tPMA z-scores in high-risk neuroblastoma patients decreased significantly following a treatment regimen that included induction chemotherapy, tumor resection surgery, and HDCT/auto-SCT. A greater decrease in tPMA z-score was associated with longer hospital stay during treatment.
Group of nonusers of antihypertensives. A subject was considered as a nonuser never received regular antihypertensive treatment or total prescription days of antihypertensives was less than 30.